Lung cancer chemotherapy agents increase procoagulant activity via protein disulfide isomerase-dependent tissue factor decryption

Blood Coagulation and Fibrinolysis

Volumn 26, Issue 1, 2015, Pages 36-45

  Lysov, Zakhar ^a,b   Swystun, Laura L ^c   Kuruvilla, Sara ^a   Arnold, Andrew ^a   Liaw, Patricia C ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c QUEEN S UNIVERSITY   (Canada)

Author keywords

A549 cells; chemotherapy; endothelium; lung cancer; monocytes; thrombosis1

Indexed keywords

ANTINEOPLASTIC AGENT; BLOOD CLOTTING FACTOR 10A; CARBOPLATIN; CISPLATIN; CYSTEINE; DITHIOTHREITOL; GEMCITABINE; GLUTATHIONE; PACLITAXEL; PHOSPHATIDYLSERINE; PROCOAGULANT; PROTEIN DISULFIDE ISOMERASE; THIOL; THROMBOPLASTIN; PLATINUM COMPLEX;

A549 CELL LINE; ANTIGEN EXPRESSION; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CELL LEVEL; CELL SURFACE; CONTROLLED STUDY; DISULFIDE BOND; ENZYME INHIBITION; HUMAN; HUMAN CELL; LUNG CANCER; MONOCYTE; PRIORITY JOURNAL; UMBILICAL VEIN ENDOTHELIAL CELL; BLOOD; CHEMICALLY INDUCED; ENZYMOLOGY; LUNG NEOPLASMS; METABOLISM; THROMBOSIS; TUMOR CELL LINE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; LUNG NEOPLASMS; ORGANOPLATINUM COMPOUNDS; PROTEIN DISULFIDE-ISOMERASES; THROMBOSIS;

EID: 84920806703     PISSN: 09575235     EISSN: 14735733     Source Type: Journal    
DOI: 10.1097/MBC.0000000000000145     Document Type: Article

References (53)

1. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005; 293:715-722.
2. Shen VS, Pollak EW. Fatal pulmonary embolism in cancer patients: is heparin prophylaxis justified? South Med J 1980; 73:841-843.
3. Ambrus JL, Ambrus CM, Mink IB, Pickren JW. Causes of death in cancer patients. J Med 1975; 6:61-64.
4. Rickles FR, Edwards RL. Activation of blood coagulation in cancer: Trousseau's syndrome revisited. Blood 1983; 62:14-31.
5. Sawada M, Miyake S, Ohdama S, Matsubara O, Masuda S, Yakumaru K, et al. Expression of tissue factor in nonsmall-cell lung cancers and its relationship to metastasis. Br J Cancer 1999; 79:472-477.
6. Rickles FR, Falanga A. Molecular basis for the relationship between thrombosis and cancer. Thromb Res 2001; 102:V215-V224.
7. Levitan N, Dowlati A, Remick SC, Tahsildar HI, Sivinski LD, Beyth R, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 1999; 78:285-291.
8. Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics, 2010. Cancer J Clin 2010; 60:277-300.
9. Azzoli CG, Giaccone G, Temin S. American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. J Oncol Pract 2010; 6:39-43.
10. Scagliotti GV, De Marinis F, Rinaldi M, Crino L, Gridelli C, Ricci S, et al. Phase III randomized trial comparing three platinum-based doublets in advanced nonsmall-cell lung cancer. J Clin Oncol 2002; 20:4285-4291.
11. Sandler A, Ettinger DS. Gemcitabine: single-agent and combination therapy in nonsmall cell lung cancer. Oncologist 1999; 4:241-251.
12. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for nonsmall-cell lung cancer. N Engl J Med 2006; 355:2542-2550.
13. Tagalakis V, Levi D, Agulnik JS, Cohen V, Kasymjanova G, Small D. High risk of deep vein thrombosis in patients with nonsmall cell lung cancer: a cohort study of 493 patients. J Thorac Oncol 2007; 2:729-734.
14. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic nonsmall-cell lung cancer. J Clin Oncol 2004; 22:2184-2191.
15. Numico G, Garrone O, Dongiovanni V, Silvestris N, Colantonio I, Di Costanzo G, et al. Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine. Cancer 2005; 103:994-999.
16. Ma L, Francia G, Viloria-Petit A, Hicklin DJ, du Manoir J, Rak J, et al. In vitro procoagulant activity induced in endothelial cells by chemotherapy and antiangiogenic drug combinations: modulation by lower-dose chemotherapy. Cancer Res 2005; 65:5365-5373.
17. Ma L, Dieckmann KP, Struss WJ, Budde U. Evidence for acute vascular toxicity of cisplatin-based chemotherapy in patients with germ cell tumour. Anticancer Res 2011; 31:4501-4505.
18. Wang HJ, Huang H, Chuang YC, Huang HC. Paclitaxel induces up-regulation of tissue factor in human aortic endothelial cells. Int Immunopharmacol 2009; 9:144-147.
19. Napoleone E, Zurlo F, Latella MC, Amore C, Di Santo A, Iacoviello L, et al. Paclitaxel downregulates tissue factor in cancer and host tumour-associated cells. Eur J Cancer 2009; 45:470-477.
20. Stephenson DA, Toltl LJ, Beaudin S, Liaw PC. Modulation of monocyte function by activated protein C, a natural anticoagulant. J Immunol 2006; 177:2115-2122.
21. Kern W, Braess J, Friedrichsen S, Kaufmann CC, Schleyer E, Hiddemann W. Carboplatin pharmacokinetics in patients receiving carboplatin and paclitaxel/docetaxel for advanced lung cancers: impact of age and renal function on area under the curve. J Cancer Res Clin Oncol 2001; 127:64-68.
22. Kroep JR, Smit EF, Giaccone G, Van der Born K, Beijnen JH, Van Groeningen CJ, et al. Pharmacology of the paclitaxel-cisplatin, gemcitabine-cisplatin, and paclitaxel-gemcitabine combinations in patients with advanced nonsmall cell lung cancer. Cancer Chemother Pharmacol 2006; 58:509-516.
23. Mechtcheriakova D, Schabbauer G, Lucerna M, Clauss M, De Martin R, Binder BR, et al. Specificity, diversity, and convergence in VEGF and TNF-alpha signaling events leading to tissue factor up-regulation via EGR-1 in endothelial cells. FASEB J 2001; 15:230-242.
24. Meszaros K, Aberle S, Dedrick R, Machovich R, Horwitz A, Birr C, et al. Monocyte tissue factor induction by lipopolysaccharide (LPS): dependence on LPS-binding protein and CD14, and inhibition by a recombinant fragment of bactericidal/permeability-increasing protein. Blood 1994; 83:2516-2525.
25. Bach RR. Tissue factor encryption. Arterioscler Thromb Vasc Biol 2006; 26:456-461.
26. Swystun LL, Mukherjee S, Levine M, Liaw PC. The chemotherapy metabolite acrolein upregulates thrombin generation and impairs the protein C anticoagulant pathway in animal-based and cell-based models. J Thromb Haemost 2011; 9:767-775.
27. Dreschers S, Gille C, Haas M, Grosse-Ophoff J, Schneider M, Leiber A, et al. Infection-induced bystander-apoptosis of monocytes is TNF-alpha-mediated. PloS One 2013; 8:e53589.
28. Zwaal RF, Schroit AJ. Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood 1997; 89:1121-1132.
29. Lentz BR. Exposure of platelet membrane phosphatidylserine regulates blood coagulation. Prog Lipid Res 2003; 42:423-438.
30. Rao LV, Kothari H, Pendurthi UR. Tissue factor encryption and decryption: facts and controversies. Thromb Res 2012; 129 (Suppl 2):S13-S17.
31. Pendurthi UR, Ghosh S, Mandal SK, Rao LV. Tissue factor activation: is disulfide bond switching a regulatory mechanism? Blood 2007; 110:3900-3908.
32. Versteeg HH, Ruf W. Tissue factor coagulant function is enhanced by protein-disulfide isomerase independent of oxidoreductase activity. J Biol Chem 2007; 282:25416-25424.
33. Weitz IC, Israel VK, Waisman JR, Presant CA, Rochanda L, Liebman HA. Chemotherapy-induced activation of hemostasis: effect of a low molecular weight heparin (dalteparin sodium) on plasma markers of hemostatic activation. Thromb Haemost 2002; 88:213-220.
34. Napoleone E, Di Santo A, Lorenzet R. Monocytes upregulate endothelial cell expression of tissue factor: a role for cell-cell contact and cross-talk. Blood 1997; 89:541-549.
35. Palomo M, Diaz-Ricart M, Rovira M, Escolar G, Carreras E. Defibrotide prevents the activation of macrovascular and microvascular endothelia caused by soluble factors released to blood by autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2011; 17:497-506.
36. Kyrle PA, Eichinger S. Deep vein thrombosis. Lancet 2005; 365:1163-1174.
37. Krudysz-Amblo J, Jennings ME 2nd, Knight T, Matthews DE, Mann KG, Butenas S. Disulfide reduction abolishes tissue factor cofactor function. Biochim Biophys Acta 2013; 1830:3489-3496.
38. Chen VM, Ahamed J, Versteeg HH, Berndt MC, Ruf W, Hogg PJ. Evidence for activation of tissue factor by an allosteric disulfide bond. Biochemistry 2006; 45:12020-12028.
39. Popescu NI, Lupu C, Lupu G. Extracellular protein disulfide isomerase regulates coagulation on endothelial cells through modulation of phosphatidylserine exposure. Blood 2010; 116:993-1001.
40. Reinhardt C, von Bruhl ML, Manukyan D, Grahl L, Lorenz M, Altmann B, et al. Protein disulfide isomerase acts as an injury response signal that enhances fibrin generation via tissue factor activation. J Clin Invest 2008; 118:1110-1122.
41. Tartier L, McCarey YL, Biaglow JE, Kochevar IE, Held KD. Apoptosis induced by dithiothreitol in HL-60 cells shows early activation of caspase 3 and isindependent ofmitochondria. Cell Death Differ 2000; 7:1002-1010.
42. Calvert AH, Harland SJ, Newell DR, Siddik ZH, Jones AC, McElwain TJ, et al. Early clinical studies with cis-diammine-1, 1-cyclobutane dicarboxylate platinum II. Cancer Chemother Pharmacol 1982; 9:140-147.
43. Perez RP. Cellular and molecular determinants of cisplatin resistance. Eur J Cancer 1998; 34:1535-1542.
44. Go RS, Adjei AA. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 1999; 17:409-422.
45. Eichholtz-Wirth H, Hietel B. The relationship between cisplatin sensitivity and drug uptake into mammalian cells in vitro. Br J Cancer 1986; 54:239-243.
46. Jamieson ER, Lippard SJ. Structure, recognition, and processing of cisplatin-DNA adducts. Chem Rev 1999; 99:2467-2498.
47. Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R, Gandhi V. Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol 1995; 22:3-10.
48. Horwitz SB. Mechanism of action of taxol. Trends Pharmacol Sci 1992; 13:134-136.
49. Lin HL, Liu TY, Chau GY, Lui WY, Chi CW. Comparison of 2-methoxyestradiol-induced, docetaxel-induced, and paclitaxel-induced apoptosis in hepatoma cells and its correlation with reactive oxygen species. Cancer 2000; 89:983-994.
50. Donadelli M, Dando I, Zaniboni T, Costanzo C, Dalla Pozza E, Scupoli MT, et al. Gemcitabine/cannabinoid combination triggers autophagy in pancreatic cancer cells through a ROS-mediated mechanism. Cell Death Dis 2011; 2:e152.
51. Preston TJ, Henderson JT, McCallum GP, Wells PG. Base excision repair of reactive oxygen species-initiated 7, 8-dihydro-8-oxo-2'-deoxyguanosine inhibits the cytotoxicity of platinum anticancer drugs. Mol Cancer Ther 2009; 8:2015-2026.
52. Swanton C, Marani M, Pardo O, Warne PH, Kelly G, Sahai E, et al. Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. Cancer Cell 2007; 11:498-512.
53. Nawrocki ST, Carew JS, Pino MS, Highshaw RA, Dunner K Jr, Huang P, et al. Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis.Cancer Res 2005;65:11658-11666.